Table 2.
pnfC1-INH usage
| Characteristics | Subjects aged ≥65 years |
|---|---|
| Subjects (n = 27) | |
| Reason for pnfC1-INH use | |
| On demand (attack treatment) only | 12 (44.5) |
| Prophylaxis only | 2 (7.4) |
| Both on demand treatment and prophylaxis | 13 (48.1) |
| Administered pnfC1-INH outside of a healthcare setting at least once | 16 (59.3) |
| pnfC1-INH infusions (n = 1701) | |
| Reason for pnfC1-INH use | |
| On demand (attack treatment) | 1511 (88.8) |
| Prophylaxis | 190 (11.2) |
| Data collection type | |
| Prospective | 841 (49.4) |
| Retrospective | 860 (50.6) |
Data are presented as n (%)
pnfC1-INH plasma-derived, highly-purified, pasteurized, nanofiltered C1-inhibitor concentrate